Brief: UCB's BIMZELX 3-Year Data Shows Lasting Efficacy In Psoriatic Arthritis, Axial Spondyloarthritis
11/06/2025 06:09
June 11 (Reuters) - Ucb SA UCB.BR: BIMZELX[®]▼(BIMEKIZUMAB) THREE-YEAR DATA AT EULAR 2025 SHOWED LASTING EFFICACY AND CONTROL OF INFLAMMATION IN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS Source text: ID:nPLX03F901 Further company coverage: UCB.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside